Orange Book product · Generic (ANDA)
TRAVOPROST
TRAVOPROST
At a glance
Mar 19, 2021
Approved
Generic (ANDA)
Application
AT2
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 19, 2021
5 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
TRAVOPROST
Strength
0.004%
Dosage form
SOLUTION/DROPS
Route
OPHTHALMIC
TE code
AT2
Application
ANDA 203767
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of TRAVOPROST
- 2023IDOSE TRBrand (NDA)
NDA 218010 · GLAUKOS
- 2014IZBABrand (NDA)
NDA 204822 · NOVARTIS
- 2006TRAVATAN ZBrand (NDA)
NDA 021994 · SANDOZ
- 2001TRAVATANBrand (NDA)
NDA 021257 · ALCON PHARMS LTD
- 2025TRAVOPROSTGeneric (ANDA)
ANDA 214687 · ALEMBIC
- 2024TRAVOPROSTGeneric (ANDA)
ANDA 217228 · SOMERSET THERAPS LLC
- 2024TRAVOPROSTGeneric (ANDA)
ANDA 218159 · GLAND
- 2024TRAVOPROSTGeneric (ANDA)
ANDA 207040 · LUPIN
- 2019TRAVOPROSTGeneric (ANDA)
ANDA 210458 · ALEMBIC
- 2017TRAVOPROSTGeneric (ANDA)
ANDA 205050 · MYLAN
- 2015TRAVOPROSTGeneric (ANDA)
ANDA 203431 · APOTEX
- 2013TRAVOPROSTGeneric (ANDA)
ANDA 091340 · CHARTWELL RX
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
